Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 44

of 'Barrett's esophagus: Treatment with radiofrequency ablation'

Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett's esophagus longer than 10 cm.
Alvarez Herrero L, van Vilsteren FG, Pouw RE, ten Kate FJ, Visser M, Seldenrijk CA, van Berge Henegouwen MI, Fockens P, Weusten BL, Bergman JJ
Gastrointest Endosc. 2011 Apr;73(4):682-90. Epub 2011 Feb 2.
BACKGROUND: Radiofrequency ablation (RFA) is safe and effective for eradicating Barrett's esophagus (BE) and BE-associated early neoplasia. Most RFA studies have limited the baseline length of BE (<10 cm), and therefore little is known about RFA for longer BE.
OBJECTIVE: To assess the safety and efficacy of RFA with or without prior endoscopic resection (ER) for BE≥10 cm containing neoplasia.
DESIGN: Prospective trial.
SETTING: Two tertiary-care centers.
PATIENTS: This study involved consecutive patients with BE≥10 cm with early neoplasia.
INTERVENTION: Focal ER for visible abnormalities, followed by a maximum of 2 circumferential and 3 focal RFA procedures every 2 to 3 months until complete remission.
MAIN OUTCOME MEASUREMENTS: Complete remission, defined as endoscopic resolution of BE and no intestinal metaplasia (CR-IM) or neoplasia (CR-neoplasia) in biopsy specimens.
RESULTS: Of the 26 patients included, 18 underwent ER for visible abnormalities before RFA. The ER specimens showed early cancer in 11, high-grade intraepithelial neoplasia (HGIN) in 6, and low-grade intraepithelial neoplasia (LGIN) in 1. The worst residual histology, before RFA and after any ER, was HGIN in 16 patients and LGIN in 10 patients. CR-neoplasia and CR-IM were achieved in 83% (95% confidence interval [CI], 63%-95%) and 79% (95% CI, 58%-93%), respectively. None of the patients had fatal or severe complications and 15% (95% CI, 4%-35%) had moderate complications. During a mean (±standard deviation) follow-up of 29 (±9.1) months, no neoplasia recurred.
LIMITATIONS: Tertiary-care center, short follow-up.
CONCLUSION: ER for visible abnormalities, followed by RFA of residual BE is a safe and effective treatment for BE≥10 cm containing neoplasia, with a low chance of recurrence of neoplasia or BE during follow-up.
Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands.